Verisante Technology said this week that it has signed an exclusive agreement with Frontière Médicale EUROPE for distribution of its Verisante Aura skin cancer detection device in the UK and Ireland.
With the agreement, Verisante now has distribution agreements for the Aura in Canada, Germany, Austria, Liechtenstein, Switzerland, the UK, and Ireland. The company began sales of the device at the beginning of the year, and recognized $235,000 in revenue from it for the quarter ended March 21, 2013.
The Aura uses Raman spectroscopy to measure the levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions to distinguish between benign and malignant lesions. By comparing the patterns of spectra generated by the device, clinicians can differentiate between the two.
According to Verisante, there are more than 650 dermatologists in Ireland and the UK, with the rate of skin cancer in Ireland almost doubling in the last 10 years.